WO1996022764A1 - Liposomes containing a corticosteroid - Google Patents
Liposomes containing a corticosteroid Download PDFInfo
- Publication number
- WO1996022764A1 WO1996022764A1 PCT/GB1996/000083 GB9600083W WO9622764A1 WO 1996022764 A1 WO1996022764 A1 WO 1996022764A1 GB 9600083 W GB9600083 W GB 9600083W WO 9622764 A1 WO9622764 A1 WO 9622764A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- liposomes
- formula
- phosphatidyl
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Definitions
- the invention relates to pharmaceutical compositions containing a particular corticosteroid as active ingredient, especially for use in the treatment of asthma by inhalation therapy, and a process for the preparation of such pharmaceutical compositions.
- bronchitis and bronchial asthma have become widespread. Their pathogenesis and severity vary from individual to individual. Extrinsic allergic bronchial asthma, caused by environmental influences (e.g. waste gases, weather inversion layers), and intrinsic bronchial asthma are often characterised by severe attacks with varying respiratory distress. The intensity of coughing and expectoration also vary. Transitional and mixed forms of asthma are frequent and have to be taken into account in therapeutic treatment.
- three defined groups of active ingredients with acceptable risk are available, apart from combination formulations. These three groups are ⁇ 2 -adrenergic agents such as adrenaline, bamethan, clenbuterol, fenoterol, sulbutamol and terbutaline, xanthine derivatives such as theophylline and diprophylline and antichlolinergics containing the atropine derivatives ipatropium bromide and oxitropium bromide.
- ⁇ 2 -adrenergic agents such as adrenaline, bamethan, clenbuterol, fenoterol, sulbutamol and terbutaline
- xanthine derivatives such as theophylline and diprophylline and antichlolinergics containing the atropine derivatives ipatropium bromide and oxitropium bromide.
- corticosteroid formulations used in existing inhalation therapy have, in addition to the desired antiallergic, antiexudative - anti-inflammatory properties, slight but undersirable systemic side effects arising from absorption of the inhaled corticosteroid.
- Inhalation therapy using corticosteroids usually has to be carried out over many years, significantly increasing the problem of systemic side effects.
- the present invention provides, in one aspect, a pharmaceutical composition
- a pharmaceutical composition comprising, as active ingredient, a compound of formula I
- the compound of formula I methyl 9 ⁇ -chloro-6 ⁇ -fluoro - ll ⁇ -hydroxy- 16 ⁇ -methyl-3-oxo-17 ⁇ -propionyloxyandrosta- 1 , 4-diene- 17 ⁇ -carboxylate, may be prepared as described in British Patent Specification No. 1 578 243.
- the liposomes may be in aqueous suspension or, in dehydrated form, as a dry powder.
- liposomes containing the compound of formula I exhibit ready uptake by alveolar macrophages and effective inhibition of eosinophil recruitment in a Brown - Norway rat model of allergen-induced eosinophilia.
- Suitable liposomes generally include those in which the lipid component comprises at least one synthetic phospholipid.
- synthetic phospholipids are synthetic phosphatidylcholines such as dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, dioleoyl phosphatidylcholine, dilinoleoyl phosphatidylcholine, dilauryloyl phosphatidylcholine, l-palmitoyl-2-oleoyl phosphatidylcholine, l-myristoyl-2-palmitoyl phosphatidylcholine and l-palmitoyl-2-myristoyl phosphatidylcholine, synthetic phosphatidylglycerols such as dilauryloyl phosphatidylglycerol, dimyristoyl phosphatidylglycerol
- the lipid component of the liposomes comprises a synthetic phosphatidylcholine such as those hereinbefore described optionally together with a synthetic phosphatidylserine or synthetic phosphatidylglycerol such as those hereinbefore described, the weight ratio of the phosphatidylcholine to the phosphatidylserine or phosphatidylglycerol preferably being from 60:40 to 95:5, especially from 70:30 to 90:10.
- the lipid component of the liposomes comprises a synthetic, substantially pure phospholipid of formula
- Rj is C 10 -C 2 o alkanoyl having an even number of carbon atoms
- R 2 is 0 -C 20 alkenoyl having an even number of carbon atoms
- R a , R b and R e are hydrogen or C C alkyl and n is an integer from two to four.
- Rj as CJQ-CTO alkanoyl having an even number of carbon atoms is preferably n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl, n-octadecanoyl or n-eicosanoyl.
- R 2 as C 10 -C 2 o alkenoyl having an even number of carbon atoms is preferably 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 6-cis-octadecenoyl, 6-trans-octadecenoyl, 9-cis-octadecenoyl, 9-trans-octadecenoyl, 11-cis-octadecenoyl or 9-cis-eicosenoyl.
- R a , R b and R ⁇ are preferably C 1 -C 4 alkyl, especially methyl.
- n is an integer from two to four, preferably two.
- Rj is n-dodecanoyl, n-tetradecanoyl, n-hexadecanoyl or n-octadecanoyl and R 2 is 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-icosenoyl, R a , R b and R ⁇ . are methyl and n is two.
- a very especially preferred phospholipid of formula ⁇ is synthetic 1 -n-hexadccanoyl-2-(9-cis-octadecenoyl)-3-sn-phosphatidyl choline.
- the lipid component comprises a phospholipid of formula II combined with a synthetic, substantially pure phospholipid of formula
- R 3 and R 4 are each independendy of the other C 10 -C 20 alkenoyl having an even number of carbon atoms
- n is an integer from one to three
- Y® is the cation of a pharmaceutically acceptable base.
- R 3 and R 4 as alkenoyl having an even number of carbon atoms are preferably 9-cis-dodece ⁇ oyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 6-cis-octadecenoyl, 6-trans-octadecenoyl, 9-cis-octadecenoyl, 9-trans-octadecenoyl, 11-cis-octadecenoyl or 9-cis-cicosenoyl.
- the cation Y® of a pharmaceutically acceptable base is, for example, an alkali metal ion, for example the lithium, sodium or potassium ion, the ammonium ion, a mono-, di- or tri- C 1 -C 4 alkylammonium ion, for example the trimethyl-, ethyl-, diethyl- or triethyl-ammonium ion, the tetramethylammonium ion, a 2-hydroxyethyl-tri-C 1 -C 4 alkyl-ammonium ion, for example the choline cation, or the 2-hydroxyethylammonium ion, or the cation of a basic amino acid, for example lysine or arginine.
- Y® is preferably the sodium ion.
- R 3 and R 4 are identical and are, for example, 9-cis-dodecenoyl, 9-cis-tetradecenoyl, 9-cis-hexadecenoyl, 9-cis-octadecenoyl or 9-cis-eicosenoyl, n is one and Y® is the sodium ion.
- a very especially preferred phospholipid of formula in is synthetic sodium 1 ,2-di(9-cis-octadecenoyl)-3-sn-phosphatidyl S-serine.
- the lipid component of the liposomes comprises a di(C 10 -C 2 o alkanoyl) phosphatidylcholine together with a di(C 10 -C 20 alkanoyl) phosphatidylglycerol, the alkanoyl groups having an even number of carbon atoms and die preferred weight ratios being as hereinbefore described
- the two alkanoyl groups may be the same or different and are preferably n-dodecanoyl (lauroyl), n-tetradecanoyl (myristoyl), n-hexadecanoyl (palmitoyl), n-octadecanoyl (stearoyl) or n-eicosanoyl.
- the di(C 10 -C 20 alkanoyl) phosphatidylcholine is distearoyl phosphatidylcholine and the di(C 10 -C 2 o alkanoyl) phosphatidylglycerol is dipalmitoyl phosphatidylglycerol.
- the lipid component of the liposomes may contain cholesterol in addition to the phospholipid(s), the amount of cholesterol being, for example, from 20 to 60, preferably 30 to 50, mol % of the total lipid content.
- d e lipid component of the liposomes comprises a synthetic phosphatidylcholine such as hereinbefore described, a syndietic phosphatidylserine or phosphatidylglycerol such as hereinbefore described and cholesterol, the preferred weight ratio of phosphatidylcholine to phosphatidylserine or phosphatidylglycerol being as hereinbefore described and die preferred weight ratio of cholesterol to the total phospholipid content being from 1:1 to 1: 5.
- die lipid component comprises dimyristoyl phosphotidyl choline, cholesterol and dioleoyl phosphatidyl serine.
- the active compound-containing liposomes of die invention can be prepared using known methods for the production of drug-containing liposomes. For example, in one method a solution of die compound of formula I and one or more lipids in an organic solvent, such as an alcohol, ether or halohydrocarbon or mixture thereof, is added gradually, preferably dropwise, to a stirred aqueous medium such as phosphate buffered saline to give an aqueous suspension of liposomes.
- an organic solvent such as an alcohol, ether or halohydrocarbon or mixture thereof
- one or more lipids and die compound of formula I are dissolved in an organic solvent, such as an alcohol, ether or halohydrocarbon or mixture thereof, the solvent is removed from the resulting solution, for example by freeze drying or by rotary evaporation, and the residue is dispersed in an aqueous medium, such as phosphate buffered saline or an aqueous solution of a sugar, e.g. lactose, to give an aqueous suspension of liposomes.
- an organic solvent such as an alcohol, ether or halohydrocarbon or mixture thereof
- the solvent is removed from the resulting solution, for example by freeze drying or by rotary evaporation, and the residue is dispersed in an aqueous medium, such as phosphate buffered saline or an aqueous solution of a sugar, e.g. lactose, to give an aqueous suspension of liposomes.
- an aqueous medium such as phosphate buffered s
- the aqueous liposome suspension can be treated by known methods to remove the solvent and reduce the size of the liposomes.
- an aqueous liposome suspension prepared by the first method described above using a water-miscible organic solvent can be subjected to dialysis, optionally after further dilution widi an aqueous medium, and d e dialysed suspension concentrated by ultrafiltration.
- An aqueous liposome suspension prepared by die first method, but using a water-immiscible organic solvent can be evaporated to remove the solvent and then concentrated by ultrafiltration.
- An aqueous liposome suspension prepared by d e second method described above, which usually results in the formation of multila ellar vesicles (MLV's), may be treated to reduce d e lipsome size by extruding it through one or more membranes, e.g. polycarbonate membranes, having a selected pore size.
- Liposomes for use according to the invention preferably have a particle size below 1 ⁇ m, more preferably 20-200 n , especially 50-100 nm.
- the liposomes containing a compound of formula I may be dehydrated, preferably by lyophilisation (freeze drying), to give a dry powder for administration by a dry powder inhaler in the treatment of asthma.
- the dehydrated liposomes become rehydrated by fluid in d e airways of a patient.
- Lyophilisation of the liposomes is generally carried out in the presence of a cryoprotectant, which may have been incorporated into the aqueous medium used in formation of the liposomes.
- the cryoprotectant is preferably a sugar, for example a monosaccharide such as glucose, a polymeric sugar such as dextran or, preferably, a disaccharide such as sucrose, lactose, maltose or trehalose.
- Especially preferred cryoprotectants are lactose and trehalose.
- primary lyophilisation is preferably carried out at a temperature below the phase transition temperature of the material to be lyophilised.
- Dehydration of die liposomes in the presence of the cryoprotectant results in the formation of a dry powder comprising a mixture of dehydrated liposomes and die cryoprotectant.
- die cryoprotectant is present in the aqueous medium in which the liposomes are formed, die cryoprotectant is on both the inner and outer surfaces of the liposome particles.
- the weight ratio of cryoprotectant to the lipid of d e liposomes is generally from 1:1 to 4:1, although lower and higher ratios can be used if desired.
- the product obtained on dehydration of d e liposomes containing the compound of formula I is ground to give a particle size suitable for use in inhalation therapy, being administered, for example, using a dry powder inhaler device.
- a suitable size is generally less than 10 ⁇ m, preferably 1 to 7 ⁇ m.
- the liposomes containing the compound of formula I may also be used in inhalation therapy in the form of a suspension in an aqueous medium, if necessary after treatment as hereinbefore described to reduce d e particle size of the liposomes to an appropriate extent.
- the liposomes may be prepared in d e aqueous medium to be used as a vehicle in inhalation therapy or they may be prepared in another medium and separated therefrom and, optionally, dehydrated as hereinbefore described before incorporation in d e aqueous medium to be used as a vehicle in inhalation therapy.
- the aqueous medium may be an aqueous medium such as is used conventionally as a vehicle in inhalation therapy; it is usually water containing dissolved therein one or more pharmaceutically acceptable excipients such as sodium chloride, buffering agents, antioxidants and surfactants.
- a convenient aqueous medium is phosphate-buffered saline, which may contain an antioxidant such as ⁇ -tocopherol.
- an aqueous liposome suspension of the invention may be administered by a known nebuliser, for example a pneumatic nebuliser.
- a dry powder of the invention containing the compound of formula I entrapped in dehydrated liposomes, may be placed in capsules, e.g. of gelatin or plastic, or blisters for use in a dry powder inhalation device.
- the capsules or blisters preferably contain dosage units of the dry powder, which may comprise, for example, 10 to 1000 ⁇ g, preferably 50 to 400 ⁇ g, of the compound of formula I together with sufficient carrier to give 4 to 40 mg, preferably 20 to 30mg, of dry powder.
- the dry powder may be placed in the reservoir of a multidose dry powder inhalation device adapted to deliver, for example, 2mg of dry powder per actuation.
- the present invention provides, in a further aspect, a method of treating asthma which comprises administration by inhalation of an effective amount of a compound of formula I as hereinbefore defined contained in liposomes or dehydrated liposomes as hereinbefore described.
- the daily dosage of the compound of formula I may vary according to die age and weight of die patient to be treated and die severity of the condition. Generally, daily doses may be in the range 50 to 2000 ⁇ g, more usually 100 to 1000 ⁇ g.
- the concentrated aqueous liposome suspension is filtered successively through filters having a pore size of 0.8 ⁇ m and 0.2 ⁇ m and dispensed into sterile vials (2 ml each vial).
- the suspension obtained is suitable for administration by nebuliser in the treatment of asthma by inhalation therapy.
- Example 1 The preparation procedure of Example 1 is repeated, but using an aqueous solution containing 94.4g per litre of lactose monohydrate and 0.24g per litre of sodium chloride in place of the phosphate buffered saline used in Example 1 for both liposome formation and dialysis, to give a concentrated aqueous liposome suspension.
- the concentrated aqueous liposome suspension prepared in Example 2 is freeze dried in a Lyovac GT4 lyophiliser.
- the cake obtained is micronised using a Trost air impact pulveriser to give a dry powder having a median particle size of 6-7 ⁇ m which is suitable for administration by a dry powder inhalation device in d e treatment of asthma by inhalation therapy.
- Distearoyl phosphatidyl choline (700 mg), dipalmitoyl phosphatidyl choline (300 mg) and Compound 1 (20 mg) are dissolved in a 2:1 (by volume) mixture of chloroform and methanol (20 ml). The solvent is removed by rotary evaporation. The residue is dispersed in 40ml of an aqueous lactose solution containing 94.4g per litre of lactose monohydrate and 0.24g per litre of sodium chloride to give an aqueous liposome suspension.
- Example 5 This suspension is extruded through 2200nm polycarbonate membranes twice and 2 lOOnm polycarbonate membranes ten times at 70°C under a head of nitrogen to reduce die particle size of the liposomes.
- the resulting suspension is lyophilised and micronised as in Example 3 to give a dry powder which is suitable for administration by a dry powder inhalation device in the treatment of asthma by inhalation therapy.
- Example 5
- Dimyristoyl phosphatidyl choline (678mg), cholesterol (193mg), dioleoyl phosphatidyl serine (81mg) and Compound 1 (20 mg) are dissolved in tert-butanol (20 ml).
- the tert-butanol is removed from the resulting solution by freeze drying.
- the residue is dispersed in an aqueous lactose solution as described in Example 4 and me liposome suspension obtained is extruded as described in Example 4, but at 35°C instead of 70°C, to reduce d e size of the liposomes to lOOnm.
- the resulting suspension is lyophilised and micronised as in Example 3 to give a dry powder which is suitable for administration by a dry powder inhalation device in die treatment of asthma by inhalation therapy.
- Group 1 The animals are sensitised by an intraperitoneal injection of 0.9% (wt vol) suspension of ovalbumin (lmg)/Al(OH)3 (100m g) (1ml) followed 21 days later by a single saline aerosol exposure for 15 minutes.
- Group 2 The animals are sensitised with ovalbumin as for Group 1, followed 21 days later by exposure to a 1% ovalbumin aerosol for 15 minutes.
- Group 3 The animals are sensitised with ovalbumin as for Group 1, followed 19 days later by a transtracheal injection of die liposome suspension (0.5ml) of Example 1 containing 3 ⁇ g of Compound 1 under ketamine anaesthesia and 24 hours later by a further such transtracheal injection. 24 hours after the second injection, d e animals are exposed to a 1% ovalbumin aerosol for 15 minutes.
- Group 4 The animals are treated as for tiiose of group 3, but using, in place of the liposomes containing Compound 1, placebo liposomes prepared by die same procedure but omitting Compound 1.
- bronchoalveolar lavage is performed 24 hours after the exposure to the aerosol to determine d e eosinophil count. The results are as follows:
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8522703A JPH10512876A (en) | 1995-01-24 | 1996-01-17 | Liposomes containing corticosteroids |
CZ972342A CZ234297A3 (en) | 1995-01-24 | 1996-01-17 | Pharmaceutical preparation containing corticosteroid and the use thereof |
AU43961/96A AU4396196A (en) | 1995-01-24 | 1996-01-17 | Liposomes containing a corticosteroid |
EP96900365A EP0859598A1 (en) | 1995-01-24 | 1996-01-17 | Liposomes containing a corticosteroid |
FI973049A FI973049A (en) | 1995-01-24 | 1997-07-18 | Corticosteroid-containing liposomes |
NO973401A NO973401D0 (en) | 1995-01-24 | 1997-07-23 | Corticosteroid-containing compositions and their preparation |
MXPA/A/1997/005592A MXPA97005592A (en) | 1995-01-24 | 1997-07-23 | Pharmaceutical compositions containing corticosteroids and preparation of mys |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9501286.0A GB9501286D0 (en) | 1995-01-24 | 1995-01-24 | Pharmaceutical compositions and preparations thereof |
GB9501286.0 | 1995-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996022764A1 true WO1996022764A1 (en) | 1996-08-01 |
Family
ID=10768424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/000083 WO1996022764A1 (en) | 1995-01-24 | 1996-01-17 | Liposomes containing a corticosteroid |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0859598A1 (en) |
JP (1) | JPH10512876A (en) |
CN (1) | CN1169115A (en) |
AU (1) | AU4396196A (en) |
CA (1) | CA2210482A1 (en) |
CZ (1) | CZ234297A3 (en) |
FI (1) | FI973049A (en) |
GB (1) | GB9501286D0 (en) |
NO (1) | NO973401D0 (en) |
WO (1) | WO1996022764A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000030654A1 (en) * | 1998-11-26 | 2000-06-02 | Britannia Pharmaceuticals Limited | Anti-asthmatic combinations comprising surface active phospholipids |
WO2001066561A1 (en) * | 2000-03-09 | 2001-09-13 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic drugs for eye diseases |
WO2002045703A2 (en) * | 2000-12-04 | 2002-06-13 | Novartis Ag | Mixtures or organic compounds for the treatmentof airway diseases |
US6824761B1 (en) | 1999-05-28 | 2004-11-30 | Britannia Pharmaceuticals Limited | Anti-asthmatic combinations comprising surface active phospholipids |
US7300667B1 (en) | 1999-05-27 | 2007-11-27 | Euro-Celtique, S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract |
US7364749B1 (en) | 1999-05-27 | 2008-04-29 | Euro-Celtique, S.A. | Preparations for the application of anti-infective and/or anti-inflammatory agents |
US7595411B2 (en) | 1997-08-18 | 2009-09-29 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Phospholipid-analogous compounds |
US20100112066A1 (en) * | 2006-09-05 | 2010-05-06 | Q.P. Corporation | Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10255285A1 (en) * | 2002-11-26 | 2004-06-03 | Mcs Micro Carrier Systems Gmbh | Self-forming phospholipid gels |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0135476A2 (en) * | 1983-08-18 | 1985-03-27 | Ciba-Geigy Ag | Carboxylic acid esters of steroids |
EP0260241A1 (en) * | 1986-09-12 | 1988-03-16 | Aktiebolaget Draco | A new system for administration of liposomes to mammals |
US5043165A (en) * | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
-
1995
- 1995-01-24 GB GBGB9501286.0A patent/GB9501286D0/en active Pending
-
1996
- 1996-01-17 EP EP96900365A patent/EP0859598A1/en not_active Withdrawn
- 1996-01-17 CN CN96191591A patent/CN1169115A/en active Pending
- 1996-01-17 JP JP8522703A patent/JPH10512876A/en active Pending
- 1996-01-17 WO PCT/GB1996/000083 patent/WO1996022764A1/en not_active Application Discontinuation
- 1996-01-17 AU AU43961/96A patent/AU4396196A/en not_active Abandoned
- 1996-01-17 CA CA002210482A patent/CA2210482A1/en not_active Abandoned
- 1996-01-17 CZ CZ972342A patent/CZ234297A3/en unknown
-
1997
- 1997-07-18 FI FI973049A patent/FI973049A/en unknown
- 1997-07-23 NO NO973401A patent/NO973401D0/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0135476A2 (en) * | 1983-08-18 | 1985-03-27 | Ciba-Geigy Ag | Carboxylic acid esters of steroids |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
EP0260241A1 (en) * | 1986-09-12 | 1988-03-16 | Aktiebolaget Draco | A new system for administration of liposomes to mammals |
US5043165A (en) * | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595411B2 (en) | 1997-08-18 | 2009-09-29 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Phospholipid-analogous compounds |
US8497388B2 (en) | 1997-08-18 | 2013-07-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften. E.V. | Phospholipid-analogous compounds |
US7939683B2 (en) | 1997-08-18 | 2011-05-10 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Phospholipid-analogous compounds |
JP2006199713A (en) * | 1998-11-26 | 2006-08-03 | Britannia Pharmaceuticals Ltd | Anti-asthmatic combinations comprising surface active phospholipids |
GB2359749B (en) * | 1998-11-26 | 2004-05-05 | Britannia Pharmaceuticals Ltd | Anti-asthmatic combinations comprising surface active phospholipids |
GB2359749A (en) * | 1998-11-26 | 2001-09-05 | Britannia Pharmaceuticals Ltd | Anti-asthmatic combinations comprising surface active phospholipids |
EP1658851A1 (en) * | 1998-11-26 | 2006-05-24 | Britannia Pharmaceuticals Limited | Anti-asthmatic combinations comprising surface active phospholipids |
WO2000030654A1 (en) * | 1998-11-26 | 2000-06-02 | Britannia Pharmaceuticals Limited | Anti-asthmatic combinations comprising surface active phospholipids |
US7273604B2 (en) | 1998-11-26 | 2007-09-25 | Britannia Pharmaceuticals Limited | Anti-asthmatic combinations comprising surface active phospholipids |
US7364749B1 (en) | 1999-05-27 | 2008-04-29 | Euro-Celtique, S.A. | Preparations for the application of anti-infective and/or anti-inflammatory agents |
US7300667B1 (en) | 1999-05-27 | 2007-11-27 | Euro-Celtique, S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract |
US6824761B1 (en) | 1999-05-28 | 2004-11-30 | Britannia Pharmaceuticals Limited | Anti-asthmatic combinations comprising surface active phospholipids |
WO2001066561A1 (en) * | 2000-03-09 | 2001-09-13 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic drugs for eye diseases |
US7008951B2 (en) | 2000-12-04 | 2006-03-07 | Novartis Ag | Mixtures or organic compounds for the treatment of airway diseases |
WO2002045703A2 (en) * | 2000-12-04 | 2002-06-13 | Novartis Ag | Mixtures or organic compounds for the treatmentof airway diseases |
US7622484B2 (en) | 2000-12-04 | 2009-11-24 | Novartis Ag | Mixtures or organic compounds for the treatment of airway diseases |
WO2002045703A3 (en) * | 2000-12-04 | 2003-03-13 | Novartis Ag | Mixtures or organic compounds for the treatmentof airway diseases |
US6800643B2 (en) | 2000-12-04 | 2004-10-05 | Novartis Ag | Mixtures for organic compounds for the treatment of airway diseases |
CZ304294B6 (en) * | 2000-12-04 | 2014-02-19 | Novartis Ag | Medicament and pharmaceutical kit |
US20100112066A1 (en) * | 2006-09-05 | 2010-05-06 | Q.P. Corporation | Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent |
US8334321B2 (en) * | 2006-09-05 | 2012-12-18 | Q.P. Corporation | Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent |
Also Published As
Publication number | Publication date |
---|---|
CN1169115A (en) | 1997-12-31 |
FI973049A0 (en) | 1997-07-18 |
EP0859598A1 (en) | 1998-08-26 |
MX9705592A (en) | 1997-11-29 |
NO973401L (en) | 1997-07-23 |
GB9501286D0 (en) | 1995-03-15 |
AU4396196A (en) | 1996-08-14 |
CA2210482A1 (en) | 1996-08-01 |
CZ234297A3 (en) | 1997-10-15 |
NO973401D0 (en) | 1997-07-23 |
FI973049A (en) | 1997-07-18 |
JPH10512876A (en) | 1998-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1257836A (en) | Inhalation method and system | |
US6770290B1 (en) | Amphotericin B liposome preparation | |
US5141674A (en) | Methods of preparing pro-liposome dispersions and aerosols | |
EP0309464B1 (en) | Membrane lipid composition and method for its preparation | |
US5283067A (en) | Parenteral suspensions | |
HUT77628A (en) | Proliposome powders for inhalation | |
EP1109533A1 (en) | Pulmonary delivery of liposome-encapsulated cannabinoids | |
Chandraprakash et al. | Pharmacokinetic evaluation of surfactant vesicle-entrapped methotrexate in tumor-bearing mice | |
BRPI0510778B1 (en) | PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF: SAME, AND, USE OF A COMPOSITION | |
US6623753B1 (en) | Allylamine-containing liposomes | |
IE914498A1 (en) | Treatment of cystic fibrosis and pharmaceutical compositions¹for use therein | |
WO1996022764A1 (en) | Liposomes containing a corticosteroid | |
US6007834A (en) | Nasal melatonin composition | |
EP1212039B1 (en) | Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent | |
EP1759699B1 (en) | Liposome preparation containing slightly water-soluble camptothecin | |
CN113456591B (en) | Glycosyl polyether compound liposome and preparation method and medicament thereof | |
CA1305058C (en) | Parenteral suspension containing diclofenac | |
WO1998042333A1 (en) | Nasal melatonin composition | |
MXPA97005592A (en) | Pharmaceutical compositions containing corticosteroids and preparation of mys | |
JPH04244017A (en) | Liposome preparation | |
EP0500802A1 (en) | Liposomal compositions. | |
JP2023518694A (en) | Antiviral composition for use in prophylactic or post-exposure treatment of infectious or respiratory disease | |
IE54532B1 (en) | Improvements in or relating to nasal pharmaceutical compositions | |
CN114788813A (en) | Andrographolide freeze-dried liposome preparation for aerosol inhalation and preparation method and application thereof | |
AU4591602A (en) | Nasal melatonin composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96191591.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LS LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN AZ BY KG KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 1997 860782 Country of ref document: US Date of ref document: 19970708 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 298467 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2210482 Country of ref document: CA Ref document number: 2210482 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 973049 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-2342 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/005592 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1996 522703 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996900365 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-2342 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996900365 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1997-2342 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996900365 Country of ref document: EP |